MAH0 Stock Chart & Stats
€0.23
>-€0.01(-1.52%)
At close: 4:00 PM EDT
€0.23
>-€0.01(-1.52%)
Day’s Range― - ―
52-Week Range€0.20 - €1.95
Previous CloseN/A
Volume0.00
Average Volume (3M)575.00
Market Cap
€34.36M
Enterprise Value€21.97
Total Cash (Recent Filing)€30.12M
Total Debt (Recent Filing)€1.03M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Nov 17, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding159,690,980
10 Day Avg. Volume0
30 Day Avg. Volume575
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.62
Price to Sales (P/S)132.86
P/FCF Ratio-2.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.58Price Target Upside1023.19% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)-0.05
Revenue Forecast (FY)€1.52M
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal reported debt limits immediate solvency pressure and leaves more flexibility than a highly leveraged biotech. Although the asset base is shrinking, the conservative capital structure can reduce interest burdens and preserve options for funding development priorities.
Rare-disease Partnership EconomicsThe Sentynl agreement creates potential non-dilutive economics while sharing commercialization and manufacturing responsibilities. If the option is exercised and development succeeds, upfront payments, milestones, and royalties could support Mereo’s pipeline without requiring it to build a large commercial infrastructure.
Differentiated Therapeutic FocusA focus on differentiated therapies for oncology and rare diseases targets areas where meaningful clinical benefit can support partnering interest and market access. This strategy can create value from specialized assets even before Mereo develops a broad commercial product portfolio.
Bears Say
Near-zero Revenue And Persistent LossesThe absence of meaningful current revenue leaves the company dependent on future clinical progress, licensing proceeds, or external financing. Persistent sizable losses also reduce earnings visibility and make near-term profitability dependent on successful development or partnership milestones.
Ongoing Cash BurnSustained negative operating and free cash flow means the business is not self-funding its development activities. Continued cash consumption increases reliance on financing or collaboration receipts and can constrain the pace of pipeline investment if funding conditions or milestone timing change.
Shrinking Asset BaseA substantially smaller asset base reduces financial flexibility relative to earlier periods and indicates that resources available to support clinical development have contracted. Combined with ongoing losses and cash burn, this may increase dependence on external capital or partner funding over time.
Mereo Biopharma Group Plc News
MAH0 FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was €0.20 and its highest was €1.95 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Mereo Biopharma Group Plc’s market cap is €34.36M.
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Nov 17, 2026 which is in 70 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Aug 11, 2026. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of -€0.007 by -€0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is -0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 159,690,980 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -€0.009 in its last earnings report, missing expectations of -€0.007. Following the earnings report the stock price went up 38.983%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Currently, no hedge funds are holding shares in DE:MAH0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-44.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group plc, a London-based biopharmaceutical firm established in 2015, specializes in developing and commercializing innovative therapies for oncology and rare conditions. Operating both in the United Kingdom and internationally, the company boasts a diverse product pipeline. Its primary oncology asset, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor, is presently undergoing Phase 1b clinical investigation for tumor treatment. Another cancer compound, Navicixizumab (OMP-305B83), has already concluded its Phase 1b clinical studies for patients battling late-stage ovarian cancer. Beyond cancer, Mereo is advancing several other promising candidates. These include Acumapimod (BCT-197), a p38 MAP kinase inhibitor, which is currently in Phase II clinical trials for addressing acute exacerbations of chronic obstructive pulmonary disease. Additionally, Leflutrozole (BGS-649), an oral aromatase inhibitor, is being developed to manage hypogonadotropic hypogonadism. Within its rare disease portfolio, Mereo features Setrusumab (BPS-804), a novel antibody designed to treat osteogenesis imperfecta, and Alvelestat (MPH-966), an oral small molecule in Phase II clinical trials for Alpha-1 antitrypsin deficiency. To bolster its research, Mereo BioPharma collaborates with The University of Texas MD Anderson Cancer Center, focusing on the evaluation of its anti-TIGIT therapeutic antibody candidate, etigilimab.
MAH0 Stock 12 Month Forecast
Average Price Target
€2.58
▲(1023.19% Upside)